AndroGel Global Regulatory Status: FDA Approval, Label Requirements, and International Standing

FDA Approval History and NDA Overview

AndroGel 1% received FDA approval on February 28, 2000, making it the first topical testosterone gel authorized in the United States. The approval was granted under NDA 021015 to Unimed Pharmaceuticals, which later became part of the AbbVie portfolio. The indication covered testosterone replacement therapy in adult males with primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

NDA 021015: The 1% Formulation

The original approval was based on clinical pharmacokinetic data demonstrating that once-daily application to the shoulders and upper arms could maintain serum testosterone in the normal male range (300 to 1,050 ng/dL) over 24 hours. The key 180-day open-label study enrolled 227 hypogonadal men across three dose groups (50 mg, 75 mg, and 100 mg of testosterone per day). At the 100 mg dose, 87% of subjects achieved mean testosterone levels within the normal range by day 30, a finding confirmed in the full label posted on the FDA Drugs@FDA database.

NDA 022506: The 1.62% Formulation

AbbVie submitted NDA 022506 for a higher-concentration 1.62% gel, approved in May 2011. The 1.62% formulation delivers equivalent testosterone exposure at lower gel volumes per actuation (20.25 mg or 40.5 mg per pump actuation), which reduces total skin-surface area covered and theoretically lowers the amount of gel available for secondary transfer. The dose range for this formulation is 20.25 mg to 81 mg per day, adjusted in 20.25 mg increments based on serum testosterone measured 2 to 8 hours after application, at least 14 days after starting therapy or after a dose adjustment. Full prescribing information is maintained at accessdata.fda.gov.

Schedule III Classification

The Drug Enforcement Administration classifies all testosterone products, including AndroGel, as Schedule III controlled substances under the Controlled Substances Act. Prescriptions are limited to 30-day supplies per the DEA's standard dispensing rules, and refills require a new written or electronic prescription in most states.

The AndroGel Label: Black Box Warning and Key Prescribing Sections

The FDA-approved full prescribing information for AndroGel is a legally binding document that outlines indication, dosing, contraindications, warnings, adverse reactions, and drug interactions. The label has been revised multiple times since 2000, with the most consequential changes occurring in 2009 (secondary exposure Black Box Warning) and 2015 (cardiovascular safety language).

Black Box Warning: Secondary Exposure

The Black Box Warning added in 2009 states that virilization has been reported in children who were secondarily exposed to testosterone through skin contact with treated adults. Cases have included prepubertal gynecomastia, advanced bone age, clitoromegaly, and increased libido in female partners. The FDA's specific label language reads:

"Virilization has been reported in children who were inadvertently exposed to testosterone gel. Children and women should avoid contact with unwashed or unclothed application sites in men using testosterone gel."

Application sites must be covered with clothing, and patients should wash their hands thoroughly with soap and water after every application. If a child or woman is exposed, the affected skin area should be washed immediately with soap and water.

2015 Cardiovascular Safety Update

In March 2015, the FDA issued a drug safety communication requiring all testosterone product labels to carry a general warning about possible increased cardiovascular risk. This directive followed an FDA Sentinel system analysis and review of several observational studies, including a 2014 PLOS ONE study (N=55,593) that found a hazard ratio of 1.36 (95% CI 1.03 to 1.81) for non-fatal myocardial infarction in the 90 days following a new testosterone prescription compared with the prior year in men aged 65 and older. The updated label states that the cardiovascular safety of testosterone has not been established by adequate and well-controlled clinical trials and that patients with pre-existing cardiac, renal, or hepatic disease may be at greater risk. The FDA safety communication is available at fda.gov.

Indication Limitations: The 2015 Clarification

The same 2015 label revision narrowed the approved indication language. The FDA required all testosterone manufacturers to clarify that the product is approved only for hypogonadism caused by an underlying medical condition, not for age-related testosterone decline, which the agency declined to classify as a treatable condition under the current evidence base. This distinction has regulatory and legal consequences for prescribers who treat men with normal-range or low-normal testosterone purely on symptom grounds.

Contraindications

The label lists the following absolute contraindications:

• Known or suspected prostate or breast carcinoma in men
• Pregnancy (Category X; teratogenic based on animal data)
• Women who are or may become pregnant

AndroGel is not indicated for use in women under any circumstance in the United States, a position that contrasts with off-label prescribing practice in some other countries for female androgen insufficiency.

Post-Market Surveillance and Major Safety Studies

Post-approval safety data on testosterone therapy has accumulated substantially since 2000. The picture is more nuanced than early observational signals suggested.

The T-Trials: Efficacy Signal with Cardiovascular Caution

The Testosterone Trials (T-Trials) were a coordinated set of seven double-blind, placebo-controlled trials conducted at 12 U.S. Sites in 788 men aged 65 or older with confirmed low testosterone (<275 ng/dL on two morning measurements) and at least one symptom domain of hypogonadism. Published in the New England Journal of Medicine in 2016, the sexual function trial showed a significant improvement in sexual desire and erectile function at 12 months in the testosterone arm versus placebo (P<0.001) [1]. The physical function and vitality trials showed more modest benefits.

The T-Trials also generated a cardiovascular sub-study showing a greater increase in noncalcified plaque volume (assessed by coronary CT angiography) in the testosterone group compared with placebo over 12 months. Mean increase was 41 mm³ versus 17 mm³ (P=0.002). This finding prompted caution, though the trial was not powered to detect hard cardiovascular endpoints like myocardial infarction or stroke. For a definitive cardiovascular outcome trial, the field turned to TRAVERSE.

TRAVERSE Trial: Clarifying Cardiovascular Risk

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, was a multicenter, randomized, double-blind, placebo-controlled trial specifically designed to evaluate testosterone replacement therapy's cardiovascular safety in men aged 45 to 80 with hypogonadism and either pre-existing cardiovascular disease or elevated cardiovascular risk. At a median follow-up of 33 months, the primary composite endpoint (non-fatal MI, non-fatal stroke, or cardiovascular death) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (HR 0.96; 95% CI 0.78 to 1.17), meeting the non-inferiority margin. The FDA subsequently updated prescribing guidance to reflect TRAVERSE's reassuring non-inferiority data, though the general cardiovascular warning language remains on label pending further review. The trial is indexed at pubmed.ncbi.nlm.nih.gov.

Polycythemia and Venous Thromboembolism

The label warns that testosterone therapy may cause polycythemia (elevated hematocrit). The FDA requires monitoring of hematocrit at baseline and periodically during treatment, with dose reduction or cessation if hematocrit exceeds 54%. A 2017 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that testosterone therapy increased hemoglobin by approximately 0.8 g/dL over 3 to 6 months. Venous thromboembolism (VTE) reports prompted an additional label warning in 2014 after FDA identified cases of deep vein thrombosis and pulmonary embolism in testosterone users through the MedWatch adverse event system.

The HealthRX clinical team has developed the following 4-step pre-prescribing checklist for AndroGel based on FDA label requirements, Endocrine Society guidelines, and TRAVERSE data. This framework is not reproduced in any current FDA-approved labeling or published clinical guideline and represents original editorial synthesis for prescriber education:

1. Confirm biochemical hypogonadism. Two morning total testosterone measurements below 300 ng/dL (Endocrine Society threshold) or below 264 ng/dL (American Urological Association threshold), drawn on separate days.
2. Rule out secondary causes. Obtain LH, FSH, prolactin, and thyroid panel before attributing low testosterone to primary or hypogonadotropic hypogonadism.
3. Screen cardiovascular and hematologic baseline. CBC (hematocrit), PSA, blood pressure, and lipid panel before initiation.
4. Document label-compliant indication. Record the confirmed clinical diagnosis of hypogonadism with etiology, consistent with the 2015 FDA indication narrowing.

Endocrine Society and Other Guideline Positions

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy in men states:

"We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs, and unequivocally low serum testosterone levels."

The guideline sets a biochemical threshold of <300 ng/dL total testosterone for initiating treatment, advises against prescribing in men with hematocrit >50%, and recommends against therapy in men with active prostate cancer, recent cardiovascular events (within the prior 6 months), or untreated severe obstructive sleep apnea. The full guideline is available at academic.oup.com. These clinical criteria broadly align with the FDA-approved indication for AndroGel.

The American Association of Clinical Endocrinology (AACE) similarly requires both biochemical confirmation and symptom burden before initiating topical testosterone. AACE disease state clinical review documents are available at aace.com.

Global Regulatory Status by Region

AndroGel itself (the AbbVie brand) is registered in multiple markets, though the regulatory pathways and approval dates differ significantly from the U.S. Chronology. Generic testosterone 1% gels are separately registered in many countries under local or regional frameworks.

European Union and United Kingdom

The European Medicines Agency has not granted a centralized marketing authorization for AndroGel under the EMA's centralized procedure. Instead, AbbVie and its licensees obtained national marketing authorizations in individual EU member states through the mutual recognition or decentralized procedure. Testogel (the equivalent product in most European markets, also manufactured by Besins Healthcare) holds national authorizations in France, Germany, the United Kingdom, and several other countries for testosterone replacement in adult males with hypogonadism confirmed by clinical features and biochemical testing.

Post-Brexit, the UK Medicines and Healthcare products Regulatory Agency (MHRA) maintains its own authorization for testosterone gel products. UK prescribing is governed by NHS clinical commissioning guidelines and NICE appraisals, which restrict first-line prescribing to confirmed primary or secondary hypogonadism with total testosterone <8 nmol/L (approximately 230 ng/dL) on two measurements.

Canada

Health Canada approved testosterone 1% gel under the brand name AndroGel through the New Drug Submission process. The Canadian product monograph carries equivalent secondary-exposure warnings to the U.S. Label and classifies testosterone as a controlled substance under Canada's Controlled Drugs and Substances Act. Health Canada's post-market safety reviews have tracked cardiovascular signal data consistent with the FDA timeline.

Australia

The Therapeutic Goods Administration (TGA) in Australia lists testosterone gel (both 1% and 2% concentrations) on the Australian Register of Therapeutic Goods (ARTG). Prescribing is restricted to PBS-listed indications for confirmed hypogonadism, and subsidized prescriptions require specialist (endocrinologist or urologist) initiation under the Pharmaceutical Benefits Scheme in most states.

Japan and Other Asian Markets

Testosterone gel formulations have been available in Japan under regulatory authorization from the Pharmaceuticals and Medical Devices Agency (PMDA), though prescribing culture and clinical thresholds differ. Japan historically set stricter lower-reference-range thresholds, and the product is less commonly prescribed relative to injectable formulations.

Markets Where AndroGel Is Not Available

AndroGel by brand is not available in many low- and middle-income countries where testosterone preparations, when approved at all, typically take the form of intramuscular injections (testosterone cypionate or enanthate). Regulatory infrastructure, cold-chain logistics, and controlled-substance scheduling barriers all contribute to limited gel availability in sub-Saharan Africa, parts of Southeast Asia, and portions of Latin America.

DEA Scheduling, Diversion Risk, and Prescribing Restrictions

As a Schedule III controlled substance, AndroGel is subject to DEA record-keeping requirements for dispensing pharmacies. Prescribers must maintain records for a minimum of 2 years. Telemedicine prescribing of testosterone is subject to the Ryan Haight Online Pharmacy Consumer Protection Act, which historically required at least one in-person evaluation before a controlled substance could be prescribed via telemedicine. The DEA's 2023 proposed rulemaking on telemedicine prescribing of controlled substances (published in the Federal Register, March 2023) created a temporary extension of pandemic-era flexibilities, and permanent rules governing remote testosterone prescribing remain in active regulatory development as of early 2025. Prescribers using telehealth platforms should verify current DEA guidance directly at dea.gov.

Compounded Testosterone Gel vs. FDA-Approved AndroGel

Compounding pharmacies produce testosterone gel in concentrations not commercially available (e.g., 2%, 5%, 10%), often at lower cost than branded AndroGel. These compounded preparations are not FDA-approved. The FDA classifies testosterone as a drug that may not be compounded under Section 503A of the Food, Drug, and Cosmetic Act if "essentially a copy" of a commercially available product, though enforcement in practice remains inconsistent. The agency's guidance on this topic is maintained at fda.gov. Prescribers should document clinical rationale when choosing compounded formulations over FDA-approved AndroGel.

Application, Transfer Prevention, and Patient Safety Requirements

The FDA label mandates specific patient counseling on transfer prevention. Patients must:

• Apply AndroGel only to clean, dry, intact skin on the shoulders, upper arms, or abdomen (site differs by formulation and label version).
• Allow the application site to dry completely before dressing.
• Wash hands immediately after application.
• Cover the application site with clothing before any skin-to-skin contact.
• Shower or wash the application site before anticipated prolonged skin-to-skin contact.

These requirements are not optional from a regulatory standpoint. Failure to counsel patients adequately has been the subject of multiple FDA warning letters to promotional materials that downplayed transfer risk.

Monitoring parameters required by the label include: serum testosterone (drawn 2 to 8 hours post-application after 14 days at a stable dose), hematocrit (baseline and periodically), PSA (baseline and at 3 to 6 months, then per prostate cancer screening guidelines), and bone density (in men with hypogonadism of long duration or osteoporosis risk, per Endocrine Society guidelines available at endocrine.org).